{"name":"Otonomy, Inc.","slug":"otonomy","ticker":"OTIC","exchange":"NASDAQ","domain":"otonomy.com","description":"Otonomy, Inc. is a biopharmaceutical company focused on the development of innovative therapeutics for the treatment of inner ear disorders. The company's lead product, Otividex (gatifloxacin otic suspension), is a fluoroquinolone antibiotic for the treatment of acute bacterial otitis externa. Otonomy has a strong pipeline of products in various stages of development, including a pipeline of otic gene therapies.","hq":"San Diego, CA","founded":0,"employees":"","ceo":"David Weber (former)","sector":"Otology / Inner Ear Therapeutics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$3M","metrics":{"revenue":125000,"revenueGrowth":-54.2,"grossMargin":0,"rdSpend":34673000,"netIncome":-51181000,"cash":77412000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Otividex patent cliff ($1.4M at risk)","drug":"Otividex","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"OTO-201","genericName":"OTO-201","slug":"oto-201","indication":"Otitis media with effusion in pediatric patients","status":"phase_3"},{"name":"OTO-201 (ciprofloxacin)","genericName":"OTO-201 (ciprofloxacin)","slug":"oto-201-ciprofloxacin","indication":"Acute otitis media with tympanostomy tubes (AOMT)","status":"phase_3"}]}],"pipeline":[{"name":"OTO-201","genericName":"OTO-201","slug":"oto-201","phase":"phase_3","mechanism":"OTO-201 is a sustained-release corticosteroid formulation designed to deliver dexamethasone directly into the middle ear to reduce inflammation and fluid accumulation.","indications":["Otitis media with effusion in pediatric patients"],"catalyst":""},{"name":"OTO-201 (ciprofloxacin)","genericName":"OTO-201 (ciprofloxacin)","slug":"oto-201-ciprofloxacin","phase":"phase_3","mechanism":"OTO-201 is a sustained-release formulation of ciprofloxacin, a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV to kill bacteria in the middle ear.","indications":["Acute otitis media with tympanostomy tubes (AOMT)","Chronic suppurative otitis media (CSOM)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Otonomy Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Otonomy reported its fourth quarter and full year 2023 financial results, including revenue of $1.4 million and a net loss of $24.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Otonomy Announces Collaboration with the University of California, San Francisco (UCSF)","summary":"Otonomy announced a collaboration with the University of California, San Francisco (UCSF) to develop a novel gene therapy for the treatment of hearing loss.","drugName":"","sentiment":"positive"},{"date":"2023-09-14","type":"regulatory","headline":"Otonomy Receives Complete Response Letter from FDA for Otividex","summary":"Otonomy received a Complete Response Letter from the FDA for its New Drug Application (NDA) for Otividex, which is a fluoroquinolone antibiotic for the treatment of acute bacterial otitis externa.","drugName":"","sentiment":"negative"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxQUDZ6dFZ2eW5wVzBNRXctS1lsNnBCU2Z4Q2YxRDdWaU5JVXR2MU5xTDFyZUIwX1ViWUl0d0V6MkQtekhlRFkzM2lmYXpHR09Fd1MwSEVmdUlPU0FhYnpyVjVaT3VrbVN5aWs3N2EwRDBmb19xOUhES1QyS29Ec09BbVlwVGFzZ3BiV1FQTnktXzJhT25CWHNBeGtvR3NxMXZnbDM3MllwS0NNQVFkcUNrX0VEOGhMWTFQMi0zaUVKbjA5dTRYMmNiOVFTLUUtb0YwSjg4REQ0TWJEcVkwQTltdGtBMUU3NkpOeUMzMWhYVWxyNUFBRXg3WXFIZm1NNnBodTdXQW94bFN6NlVfNTZtUVhQUFVjSVBGVVNzSWRRaXFCcFBlaXhLUg?oc=5","date":"2024-10-30","type":"trial","source":"GlobeNewswire","summary":"Advancements in Sensorineural Hearing Loss Clinical Trial - GlobeNewswire","headline":"Advancements in Sensorineural Hearing Loss Clinical Trial","sentiment":"neutral"},{"date":"2023-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxNa3pWX0V5T09KMl9RRkZfbDZSYmlRUTF5cEJjVXI0elZJc3VCVkdadU9QN2pRSHBqSkxOOXk3Q2tkZ3RsWkJoNTVjTzhpRVMwZEl4cnBoeWsyOVhTZ3NXbXFNa1N2bjk0aWlRUHVtVVBNNDJRYjNEQndkanRUbXFtcGFmLUNsOG9aTDJWWWozUUtaQmwyemFzVlNsLTZodU5EaUV6VUwzZUxwVnRhQTB3RmQ3Z0c5Vl90V1JBV2F3NnNneU9BajltcFF5dUx1ZmRlOURaWU1ZaFBsdFNCcFJuWUZZZGlJOVVyZWxhaDZoWm41cHFicEhNODRuM0U4UkVMTjNDeUR1dw?oc=5","date":"2023-03-29","type":"deal","source":"PR Newswire","summary":"Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board - PR Newswire","headline":"Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board","sentiment":"neutral"},{"date":"2023-03-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-02-16","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNWjVzck9NcEpCVGotOUk5MHFieGQtNkxyNGN1dEFnRm9RTDdYNWdNUk96aWlxcC00dEZNeTJkYVFFWkpsM1JSUDhic0dVZms0OEZqN1dNX1NpcjcwdjhQMk9lNmdUSGM3dU5TMEExdjlzNVVPMmpCdk1ncFZ1Q1dkTWNKY25SQQ?oc=5","date":"2022-12-20","type":"pipeline","source":"BioPharma Dive","summary":"Hearing loss biotech Otonomy plans to dissolve - BioPharma Dive","headline":"Hearing loss biotech Otonomy plans to dissolve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZTdCaG9QS2JHazZCbGNHc2NsQjV1enBjMUZYVHpHODRqdDNxMUI2ckdKaWdGUVNDajJKbDRRNVJ0S0R6R3ZEbzY4cFZNOGg4bWhfREdnclhxeTVGanBlYUtvYzcwLXV5dS0zUWVTVWowYmtnMTA4R0VieEFZQ2dGczBoaUxiaEFzV3ZmR3FZcDFJcjlEa1lOWnJ4c05EallXMUM1Z3BMY2hRZw?oc=5","date":"2022-12-20","type":"pipeline","source":"Fierce Biotech","summary":"Otonomy shuts up shop, lays off all employees after string of ear drug failures - Fierce Biotech","headline":"Otonomy shuts up shop, lays off all employees after string of ear drug failures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQTXFsWm4wazNEUU9pODdBcExYc3hCaUZkdUNIaG5ydXdXbXRpelBZdDhUZFFkRGJITzNaQTJhbThyd2ZjbEZTV1VfMWZHemhrUURPdkhPTWk5RWRYbTRxdExzYVJEajBkeXVjVDFKRXFZRzN5V2NnQ1BZcDdwd3lJSm5vSGY0Zw?oc=5","date":"2021-11-13","type":"deal","source":"The Hearing Review","summary":"Otonomy Partners with Kyorin Pharmaceutical on Hearing Loss Compound - The Hearing Review","headline":"Otonomy Partners with Kyorin Pharmaceutical on Hearing Loss Compound","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPc2ZHc2JucURIcV9wWXpCZVdsUXFBX3BjWUtENjE2OGU0OTBzdFFoa0NELUI1RUxPM0dJLU1GWmFhWGc4V2ZGb3dTS1RicnhNNnlUaHhRZGdZZnAxRzBfN0dYUm1RQXdmZnBHeVRIYjR1LXI1aWE0S1NVOU96ZGYzVWEyekNIa2FpbWQyQUhuel9DZ1ZKMlE2RGxjX1k2SGtBOEVHdER6Z0tOQW1yNllYekxpakhxekhoWGcwbDlfZEQ4N1RfaFpIdFRqc3g2Nm03U0lnWFRxbVZ6bEI1?oc=5","date":"2021-06-03","type":"deal","source":"BioSpace","summary":"ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients - BioSpace","headline":"ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patie","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE1JY2hlUmVlT3dYa3ZiTF9kbWtyR2pCdjZxV2ladlRKSlBUekZ4OVpRbGlpWm9KVmVBOHp1Q1RVX2ExZnI1NXU3aTBaNzRmUQ?oc=5","date":"2020-08-08","type":"pipeline","source":"Stock Titan","summary":"Latest OTIC News - Otonomy Announces Change in Stock Exchange ... - Stock Titan","headline":"Latest OTIC News - Otonomy Announces Change in Stock Exchange ...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxObE9vQjROeXlLZE5fMVNLVnBWSGQwQXM5a3Q4WlB1b2EwLXF0blBNZThRdmZOWW9TTkJBbG85LTlEYnR6WmpTWDRUa1FZS3pjLUhzSEZicHRWZDNvV2MzN2FaYU1EMllyaTJWQUdnV1RDRkdlbk5nYlBneTFfWF81UjRia2tpczI0d0EyWVZjZEpUcm94TGNnNEFhdXBvNkJTNWtGY0Z5MHFtOWhPemJzNmlDalZtY09KOURUVHFHTmltRXRMWjNvZjBTNXd3VDNmWnpxUTBkT01QME0zN1lTNFg5TDVhN2MzcDNFSF8zODBlYjFhazllZmRrajhOTE42NTR4RlU1SzFscXlM?oc=5","date":"2020-08-03","type":"deal","source":"GlobeNewswire","summary":"Otonomy Announces Exclusive License Agreement with Kyorin - GlobeNewswire","headline":"Otonomy Announces Exclusive License Agreement with Kyorin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxONlBaaExOTXVHREdlTlEzaEtBb2ttOTdDbW92YW40aDFCRTdTSzhiczk5LVZIRlVVdlVGREtVeUxtT2dxTjlPS1ZnQUJJUm1QUlVPUlhjVTFheThJRnFvZTdhX0F6amFTcUZRME5BNTY5YnljNTFrOW8zNFd1RkZORXp5Q3R0Nkct?oc=5","date":"2017-09-14","type":"pipeline","source":"Yahoo Finance","summary":"Billionaire Efrem Kamen Pulled Cash From Otonomy Inc (OTIC) and Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Welcoming Gilead Sciences, Inc. (GILD) - Yahoo Finance","headline":"Billionaire Efrem Kamen Pulled Cash From Otonomy Inc (OTIC) and Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Welcomi","sentiment":"neutral"}],"patents":[{"drugName":"Otividex","drugSlug":"gatifloxacin-otic-suspension","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000}],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Intersect ENT, Inc.","Sonus Pharmaceuticals, Inc.","Ocular Therapeutix, Inc."],"therapeuticFocus":["Otology / Inner Ear Therapeutics"],"financials":{"source":"sec_edgar+yahoo","revenue":125000,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":125000,"period":"2021-12-31"},{"value":273000,"period":"2020-12-31"},{"value":600000,"period":"2019-12-31"},{"value":745000,"period":"2018-12-31"},{"value":1236000,"period":"2017-12-31"},{"value":683000,"period":"2016-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":34673000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-51181000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":77412000,"cashHistory":[],"totalAssets":95637000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}